Bictegravir(GS-9883)|cas 1611493-60-7|DC Chemicals

Cas No.:	1611493-60-7
Chemical Name:	Bictegravir
Synonyms:	Bictegravir;8GB79LOJ07;Bictegravir [INN];Bictegravir [USAN:INN];GS 9883;Bictegravir (USAN/INN);BDBM330048;BCP25703;s5911;DB11799;SB18851
SMILES:	FC1C([H])=C(C([H])=C(C=1C([H])([H])N([H])C(C1C(C(=C2C(N3[C@@]([H])(C([H])([H])N2C=1[H])O[C@]1([H])C([H])([H])C([H])([H])[C@@]3([H])C1([H])[H])=O)O[H])=O)=O)F)F
Formula:	C₂₁H₁₈F₃N₃O₅
M.Wt:	449.3799
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Bictegravir is a novel, potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.

In Vitro:

Bictegravir (BIC) inhibits the strand transfer activity with an IC50 of 7.5± 0.3 nM. Relative to its inhibition of strand transfer activity, Bictegravir is a much weaker inhibitor of 3′-processing activity of HIV-1 IN, with an IC50 of 241±51 nM. Bictegravir enhances the accumulation of 2-LTR circles ~5-fold relative to the mock-treated control and reduces the amount of authentic integration products in infected cells by 100-fold. Bictegravir potently inhibits HIV-1 replication in both MT-2 and MT-4 cells with EC50s of 1.5 and 2.4 nM, respectively. Bictegravir exhibits potent antiviral effects in both primary CD4+ T lymphocytes and monocyte-derived macrophages, with EC50s of 1.5±0.3 nM and 6.6±4.1 nM, respectively, which are comparable to values obtained in T-cell lines[1].

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC11397	TAK-779	TAK-779 is a potent and selective nonpeptide antagonist of CCR5 and CXCR3, with a Ki of 1.1 nM for CCR5, and effectively and selectively inhibits R5 HIV-1, with EC50 and EC90 of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells.
DC7266	Rilpivirine(R 278474, TMC 278)	Rilpivirine(R 278474, TMC 278) is a type of anti-HIV medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI).
DC5902	Emtricitabine	Emtricitabine is a nucleoside analogue which inhibits the reverse nucleoside transcriptase enzyme. Structurally this antiviral agent is similar to Lamivudine. This agent is effective at targeting HIV and HBV viruses since these viruses replicate in a reve
DC10250	Dolutegravir Sodium	Dolutegravir is a HIV integrase inhibitor with IC50 of 2.7 nM.
DC7273	Dolutegravir	Dolutegravir (DTG, GSK1349572) is an integrase inhibitor(IC50= 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.
DC9700	BMS-707035	BMS-707035 is a potent, specific, and reversible HIV-I integrase (IN) inhibitor that blocks HIV IN strand transfer activity.
DC10890	Bictegravir	Bictegravir is a novel, potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.
DC3150	Atazanavir	Atazanavir is a HIV protease inhibitor with Ki of 2.66 nM.